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Abstract: Embryonic stem cells (ESCs), which are derived from the undifferentiated inner cell mass of the embryo, can differentiate every
cell type of the body regarding their pluripotency. Therefore, human or mouse ESCs can be used as an unlimited cell source for numerous
researches or therapeutical approaches. However, pluripotency maintenance of ESCs during in vitro culture is challenging because of
their endless differentiation capacity. In the current study, the effect of USP7 on pluripotency maintenance of mouse ESCs (mESCs) has
been investigated with the help of cell viability assay, morphological analysis, alkaline phosphatase (ALP) staining, qPCR analysis, and
Western Blotting. 600 nM P5091 application, which showed no significant toxicity in mESCs, increased the total ubiquitinated protein
amount as a proof of the accomplishment of proper USP7 inhibition. Morphological analysis and ALP activity evaluation indicated that
dual inhibition of GSK3 and MEK together with leukemia inhibitory factor (LIF) treatment protects the pluripotency in presence of
active USP7 enzyme. Yet, inactivation of USP7 reduced the ALP activity and altered the cell morphology in each treatment group. This
morphological change and decreased ALP activity refer to differentiated mESCs. These findings were supported by gene expression and
protein analysis. Gene expressions and protein amounts of pluripotency related Oct4, Nanog, c-Myc, Sox2 and Klf4 transcription factors
decreased significantly after USP7 inhibition. Together with this observation, a remarkable reduction in β-Catenin expression was also
noticed. It was also observed that USP7 inactivation shortens the half-live of β-Catenin and GSK3β proteins. This study demonstrates
that USP7 activation is crucial for proper pluripotency maintenance, which is provided through β-Catenin stabilization.
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1. Introduction
The number of researches that focused on embryonic
stem cells (ESCs) is increasing because of the endless
differentiation potential of ESCs. These researches provide
a variety of possibilities for developing better techniques to
differentiate ESCs into any cell type. For instance, from the
perspective of regenerative medicine, ESCs can be used as
an unlimited source for various tissue replacements (Zhu
et al., 2019). Keeping ESCs at pluripotent state is crucial
but challenging due to their high differentiation capacity.
The regulation of pluripotency maintenance of ESCs is
controlled by several transcription factors such as Oct4,
Sox2, and Nanog (Do and Schöler 2009). Furthermore,
cDNA microarray studies showed that those transcription
factors are important for regulation of different pathways,
such as Wnt/β-catenin pathway (Cheng et al., 2015).
The Wnt gene family is responsible for several
glycoprotein secretions which can be used as ligands to
promote numerous signaling pathways. Thus, Wnt signaling
plays a crucial role in adults as well as it does in embryonic

development (Clevers, 2006). There are three types of Wnt
pathways: canonical Wnt pathway, noncanonical planar
cell polarity pathway, and noncanonical Wnt/Ca+2 pathway.
All of the pathways are triggered by the attachment of Wnt
ligand to the corresponding receptor (Frizzled family
receptor) on the cell membrane (Adamska et al., 2010).
The planar cell polarity pathway of Wnt signaling is crucial
for cytoskeleton organization through the activation of
various proteins (Sebbagh and Borg 2014). In addition to
that, the noncanonical Wnt/Ca+2 pathway plays a critical
role in actin polymerization (Komiya and Habas 2008).
Wnt/Ca+2 pathway also has a huge impact on cellular
adhesion and migration capability of cells (Kumar et al.,
2015). The downstream of the most studied Wnt gene
family member, Wnt/β-Catenin pathway, was previously
correlated with the pluripotency maintenance of mouse
and human ESCs (ten Berge et al., 2011). In this pathway,
activated Wnt receptor triggers Dvl protein, which is
responsible for the inhibition of destruction complex
formation (Kimelman and Xu 2006). Axin and GSK3β
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proteins as crucial members of destruction complex, plays
a critical role in proteasomal degradation of β-Catenin
protein (Wu and Pan 2010). Therefore, Wnt pathway aims
to rescue β-Catenin from ubiquitination and proteasomal
degradation (Gwak et al., 2006; Chen et al., 2020). It is
known in the literature that Wnt signaling is also required
for proper reprograming of somatic cells (Lluis et al.,
2008). Furthermore, several studies on Wnt signaling
demonstrated that it is critical not only for pluripotency
maintenance but also in differentiation process of stem
cells. Thus, the real impact of Wnt/β-Catenin pathway is
its effect on cellular homeostasis of stem cells (Davidson et
al., 2012). Therefore, the regulation of β-Catenin protein,
which is controlled by ubiquitin- proteasome system
(UPS), is highly important for cellular homeostasis (Gao
et al., 2014).
Ubiquitination, which can be defined as tagging
unwanted proteins for proteasomal degradation, was
previously correlated with pluripotency maintenance
of ESCs (Suresh et al., 2016). Ubiquitination process
of proteins can be reversed for rescuing proteins from
proteasomal degradation. This process is called deubiquitination and several deubiquitinases (DUBs)
were identified as a key player in the stabilization of
proteins (Mevissen and Komander 2017). Ubiquitin
specific protease (USP) deubiquitination family member
USP7 controls several cellular mechanisms through
the stabilization of numerous proteins (Nicholson and
Suresh Kumar 2011). Previously, USP7 was correlated
with neural progenitor cell maintenance due to rescuing
repressor element 1-silencing transcription factor (REST)
from proteasomal degradation (Huang et al., 2011). In
addition to this, recent studies have shown that USP7
deubiquitination enzyme is also important in pluripotency
maintenance of human ESCs with its ability to stabilize
Nanog, Sox2 and Oct4 (Wei et al., 2019).
Identification of ubiquitination mechanisms that is
important in ESCs maintenance might be very useful
for in vitro studies as well as for future cellular therapy
approaches. Therefore, the current study aims to identify a
novel target for USP7 enzyme in pluripotency maintenance
of mouse ESCs. The effect of USP7 on mouse ESCs was
evaluated by inactivation of USP7 enzyme activity using
small molecule inhibitor, P5091.
2. Materials and methods
2.1. Cell culture
During the expansion and culture of mouse embryonic
stem cell line, R1/E (ATCC, SCRC-1036™), the
pluripotency of cells was maintained with feederdependent culture technique. Briefly, cells were cultured
in Dulbecco’s Modified Eagle Medium (DMEM, Gibco,
UK) supplemented with 15% embryonic stem-cell

FBS (Gibco, UK), L-glutamine (Gibco, UK), 1× MEM
nonessential amino acids (from 100× stock; Gibco, UK),
10 ng/mL recombinant mouse leukemia inhibitory factor
(LIF, Abmgood, Canada) and 1% penicillin, streptomycin,
and amphotericin B (PSA, Gibco, UK) on mitomycin C
(8 µg/mL, Fisher Scientific, UK) treated mouse embryonic
fibroblast (MEF) (ATCC, SCRC-1040) feeders. The cells
were incubated in humidified incubator at 37 °C and 5%
CO2 conditions.
R1/E cells were separated from MEF feeder cells
to identify the effect of P5091 on the pluripotency
of embryonic stem cells. mESCs and MEF cells were
trypsinized, and the cell suspension was replated on a
tissue culture plate. After 30 min of incubation at 37 °C,
all MEFs were observed to be attached to the surface and
the unattached, embryonic cells were resuspended in
N2B27 medium (DMEM/F12 (Gibco, UK): Neurobasal
Medium (Invitrogen, Gibco, UK) (1:1) supplemented with
0.5% N2 supplement (Gibco, UK), 1% B-27 supplement
(Gibco, UK), 0.5% of 10% Bovine serum albumin (BSA)
in phosphate buffer saline (PBS) (Sigma, USA), 1%
L-glutamine (Sigma, USA) and 1% Antibiotic-Antimycotic
(100X, Gibco, UK)) and plated on Matrigel (0.2µg/mL, BD
Biosciences, Germany)– Gelatin (0.1%, Bioshop, Canada)
(1:200) coated well plates. The pluripotency of mESCs
was maintained by the application of two small-molecule
inhibitors (2i) (3 μM CHIR99021 (CHIR, StemCell
Technologies, Canada) and 1 μM PD0325901 (PD03,
StemCell Technologies, Canada)) and 10 ng/mL LIF.
Furthermore, M15 medium (Knock-Out DMEM (Gibco,
UK), 15% fetal bovine serum (Gibco, UK) 1% AntibioticAntimycotic, 1% non-essential amino acids (100x, Gibco,
UK), 0.1 mM β-mercaptoethanol (Sigma, Germany) and
103 U/ml LIF (Abmgood, Canada)) was used to evaluate
whether the 2i application alters the possible effect of
P5091 on R1/E cells (Yang et al., 2017).
2.2. Preparation of small molecules
P5091 (Selleckchem, USA), CHIR and PD0325901 were
dissolved in dimethyl sulfoxide (DMSO, Merck Millipore,
Germany) to prepare 6 mM, 3 Mm, and 1 mM stock
solution, respectively. CHX (Cycloheximide, AppliChem,
Germany) was dissolved and diluted in M15 medium to a
final working concentration of 50 μg/mL.
2.3. Determination of non-toxic P5091 dose
To determine the non-toxic P5091 dose on R1/E cells,
3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium (MTS) assay
(CellTiter96 AqueousOne Solution; Promega UK Ltd.,
UK) was performed. mESCs were seeded on MatrigelGelatin coated 96-well plates (Corning, NY, USA) at
density of 5x103 cells/well. After overnight incubation,
cells were treated with various P5091 concentrations (100
nM, 300 nM, 600 nM, 1µM, 3 µM, 6 µM) for 24 h. The
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viability of cells was measured by using PBS containing
4.5 g/L glucose and 10% MTS as described previously
(Hayal et al., 2020). After 90 min of incubation in dark
and humidified incubator, the viability was indicated via
absorbance analysis at 490 nm.
2.4. Morphological analysis
mESCs were treated with the combinations of 2i, LIF and
P5091 in N2B27 (or only P5091 treatment in M15 medium
compared with M15 medium control) morphological
changes of cells were observed under light microscope.
Images were taken via ZEISS microscopy, AxioCam ICc
5 camera and ZEN 2 (blue edition) computer application.
Additionally, the percentage of undifferentiated cells were
calculated by using ImageJ software.
2.5. Alkaline phosphatase (ALP) staining
To analyze the change in pluripotency of mESCs, alkaline
phosphatase staining (ThermoFisher scientific, Germany)
was conducted according to manufacturer’s instructions.
Briefly, mESCs were seeded on Matrigel- Gelatin coated
12-well plates (Corning, NY, USA) at density of 4 x 104
cells/well. mESCs were treated with 600 nM P5091 in
presence of 2i and/or LIF for 24h. To stain ALP in living
cells, mESCs were washed once with DMEM/F12 (Gibco,
UK). After washing step, stock stain (500 X) was diluted
to the final concentration of 1 x with DMEM/F12. After
30 min of incubation at 37 °C, mESCs were washed
three times with DMEM/F12 before imagining by using
fluorescent microscope (ZEIS, AxioVert A1).
2.6. Quantitative real-time PCR analysis (qPCR)
Primer-BLAST
software
(National
Center
for
Biotechnology, USA) was used to design USP7, SOX2,
C-MYC, OCT4, KLF4, Brachyury, SNAIL, CDH1,
GAPDH, WNT3a, Vimentin, Axin and β-Catenin primers
(Table), which were synthesized by Sentegen. Total RNA
was isolated using TRIZOL (Invitrogen, USA) according
to manufacturer’s instructions and cDNA was synthesized
by using iScript cDNA synthesis Kit (BioRad, USA).
Quantitative real-time PCR was performed with CFX96
qPCR system (BioRad, USA) and SYBR green method
was used to detect the alterations in transcription of target
genes.
2.7. Western blot
Changes in pluripotency related Nanog, Oct4, c-Myc and
Sox2 proteins were determined by western blot analysis.
Additionally, successful decrease in de-ubiquitination
activity of USP7 and alterations in Gsk3β and β-catenin
proteins were also demonstrated by western blotting.
Furthermore, the half-life of proteins was also determined
after inhibition of translation by 50 μg/mL CHX treatment
via immunoblotting (Lamberto et al., 2017; Ji et al., 2019).
After each time point of CHX treatment, the cells were
pelleted for protein isolation. Total protein was isolated
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by using RIPA lysis buffer system (Chem Cruz, Germany)
according to manufacturer’s instructions. The proteins,
each in 30 μg, were separated into their weight via SDSPage electrophoresis and transferred to PVDF membrane
(BioRad, USA). 5% Blotting Grade Blocker (BioRad,
USA) was used to block the membrane for 1 h at room
temperature. Nanog (1:1000, SantaCruz, USA), Oct4
(1:500, SantaCruz, USA), c-Myc (1:1000, Cell Signaling
Technology, USA), Sox2 (1:500, SantaCruz, USA), Gsk3β
(1:1000, Cell Signaling Technology, USA), β-catenin
(1:1000, Cell Signaling Technology, USA) and ubiquitin
(1:1000, Cell Signaling Technology, USA) specific primary
antibodies were applied in blocking solution overnight at
4°C. After washing three times with Tris Buffered SalineTween 20 (TBST), membrane was incubated with proper
HRP linked secondary antibody (anti-rabbit or antimouse, 1:10000, Cell signaling Technology, USA) for 2 h
at room temperature and incubated with Amersham ECL
Detection Reagents (Sigma, Germany) for 30 s. As an
internal control, GAPDH specific antibody (1:10000, Cell
Signaling Technology, USA) was used, and the images were
taken by using the luminometer system (BioRad, USA).
2.8. Statistical analysis
All experiments were repeated at least three times,
and statistical analysis was conducted by using oneway ANOVA and post hoc Tukey test. The statistical
significance of P values (less than 0.05) was calculated by
using GraphPad Prism 8.0 (GraphPad Software, La Jolla,
CA, USA) software.
3. Results
3.1. P5091 treatment has no significant effect on cell viability
MTS assay was performed to identify the effect of P5091
on viability of mESCs. Various concentrations (100 nM,
300 nM, 600 nM, 1 µM, 3 µM, and 6 µM) of P5091 were
applied to mESCs for 24 h. Results showed that application
of P5091 at low concentrations (100 nM, 300 nM and 600
nM) did not affect the cell viability of mESCs (Figure 1a).
However, 1 µM, 3 µM, and 6 µM P5091 treatments decreased
the viability of mESCs by 42%, 54%, and 59%, respectively
(Figure 1a). Additionally, half of mESCs were observed
to be dead after 889.7nM P5091 application (Figure 1b).
Furthermore, selected, non-toxic concentration (600 nM)
of P5091 increased total ubiquitination levels significantly
(≈ 12-fold) indicating the successful inhibition of USP7
enzyme activity by small molecule inhibitor, P5091, in
vitro (Figure 1c).
3.2. USP7 inhibition effects the morphology and ALP activity of mESCs
To identify the impact of USP7 inhibition on mESCs
morphology, cells were treated with 600 nM P5091 in the
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Table. Primer designs used in qPCR analysis.
Gene
USP7
SOX2
C-MYC
OCT4
KLF4
Brachyrury
SNAIL
CDH1
WNT3a
GAPDH
Vimentin
AXIN
β-Catenin

Side

Sequence

Product Length

Forward

5’ CAGTCTGTAACCCGACTTCC 3’

Reverse

5’ CAGTCTGTAACCCGACTTCC 3’

Forward 5’ TTTGTCCGAGACCGAGAAGC 3’
Reverse

5’ CTCCGGGAAGCGTGTACTTA 3’

Forward

5’ CGACTACGACTCCGTACAGC 3’

Reverse

5’ GTAGCGACCGCAACATAGGA 3’

Forward

5’ TGTTCAGCCAGACCACCATC 3’

Reverse

5’ GCTTCCTCCACCCACTTCTC 3’

Forward 5’ GAAGGGAGAAGACACTGCGT 3’
Reverse

5’ GGGGGAAGTCGCTTCATGTG 3’

Forward

5’ GTTCCCGGTGCTGAAGGTAA 3’

Reverse

5’ GCGAGTCTGGGTGGATGTAG 3’

Forward 5’ CTCCAAACCCACTCGGATGT 3’’
Reverse

5’ AGCCAGACTCTTGGTGCTTG 3’

Forward 5’ AACCCAAGCACGTATCAGGG 3’
Reverse

5’ GAGTGTTGGGGGCATCATCA 3’

Forward

5’ CTCAGCTATGAACAAGCACAAC 3’

Reverse

5’ TGTTTCTCCACCACCATCTC 3’

Forward 5’ AGGAGAGTGTTTCCTCGTCC 3’
Reverse

5’ TGCCGTGAGTGGAGTCATAC 3’

Forward

5’ GCGAGAGAAATTGCAGGAGG 3’

Reverse

5’ CCGTTCAAGGTCAAGACGTG 3’

Forward

5’ CTCTGGGCTCAGGCTCC 3’

Reverse

5’ CACTCTCACCAGCCCTCTC 3’

Forward 5’ ATCATTCTGGCCAGTGGTGG 3’
Reverse

5’ AAGTCGCTGACTTGGGTCTG 3’

presence of 2i and/or LIF for 24 h on Matrigel- Gelatin coated
plates and morphological alterations were determined
by microscopic analysis. Results were determined that
morphology of mESCs were affected by P5091 treatment.
2i and LIF application caused no significant change in cell
morphologies of mESCs as expected. Yet, the addition of
P5091 changed the morphology of mESCs to form spindlelike formation. Additionally, in every group, inactivation of
USP7 resulted in impaired cellular morphology. Obtained
results also showed that inhibition of ERK and GSK3β by 2i
treatment and functional USP7 de-ubiquitination enzyme
are required for pluripotency maintenance (Figure 2a).
Furthermore, morphological analysis indicates that mouse
embryonic stem cells might undergo differentiation
after USP7 inhibition by P5091 treatment. Alkaline
phosphatase (ALP) staining revealed that active ALP
enzyme level decreased by 2-fold after P5091 treatment

184 bp
146 bp
195 bp
100 bp
82 bp
176 bp
97 bp
94 bp
198 bp
187 bp
112 bp
104 bp
192 bp

in 2i+LIF group. Similar effect was observed in 2i treated
group (57% decrease in ALP activity). However, there was
no noticeable change in the ALP activity in LIF treatment
group (Figure 2b). Together with LIF application, the dual
inhibition of GSK3 and MEK is also correlated with the
pluripotency maintenance of embryonic stem cells. Thus,
to evaluate whether the effect of P5091 on pluripotency
maintenance is dual inhibition related, cells were grown
in M15 medium without 2i application, and then they
got analyzed for differentiated cells with the help of ALP
staining. Obtained results indicate that the percentage of
undifferentiated cells were dropped significantly (44%)
after USP7 inhibition (Supplementary Figure 1).
3.3. P5091 treatment decreases the expression levels of
pluripotency related genes
To examine whether inhibition of USP7 has an effect
on pluripotency, SOX2, OCT4, C-MYC, and KLF4 gene
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Figure 1. Non-toxic dose of P5091 inhibits USP7 enzyme activity in mESCs in vitro. A. Cell viability analysis of mESCs cells treated
with various P5091 concentrations (0.1 µM, 0.3 µM, 0.6 µM, 1 µM, 3 µM, and 6 µM). No toxicity was observed for 0.6µM treatment. B.
IC50 determination of P5091. 889.7 nM of P5091 treatment killed half of the mESCs in vitro. C. Total ubiquitination of mESCs with or
without 0.6µM P5091 treatment. Amount of ubiquitin protein was found to be increased which indicates a successful inhibition of USP7
activity. Mean ± SD; n = 3 independent experiments; one-way ANOVA, *p < 0.05, compared with control group.
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Figure 2. Inactive USP7 is responsible for decreased pluripotency of mESCs. A. USP7 inactivation changes the morphology of mESCs in
vitro. Arrows indicate the morphological alterations of mESCs after 0.6 µM P5091 treatment for 24 h. B. ALP staining of all experimental
groups indicates that USP7 inactivation decreases ALP activity, which is also correlated with pluripotency. Histogram shows the ALP
activity in each group. Scale bar: 200 μm. 2i CHIR99021 (3 μM) and PD0325901 (1 μM) treatment, LIF Leukemia inhibitory factor, ALP
Alkaline Phosphate. Mean ± SD; n = 3 independent experiments; one-way ANOVA, *p < 0.05.

expression levels were determined in mESCs by gene
expression analysis. Additionally, alterations in gene
expression levels of mesoderm marker, Brachyury (T/Bra),
ectoderm marker (Vimentin), extra cellular matrix (ECM)
related CDH1 and SNAIL were also examined. Lastly,
changes in gene expression levels of WNT3a and β-Catenin,
which play a critical role in pluripotency homeostasis,
were checked by qPCR analysis. All experimental groups
were compared to relevant treatment groups including
active or inactive USP7 protein to identify any possible
change in pluripotency of mESCs. Gene expression profile
of USP7 reduced by 10-fold after P5091 treatment in 2i
+ LIF group. A dramatic decrease was observed in gene

expression levels of SOX2 (125-fold), C-MYC (142-fold),
OCT4 (13-fold), KLF4 (320-fold), WNT3a (8.5-fold) and
β-Catenin (6.25-fold) after inactivation of USP7 in 2i +
LIF group. Similarly, in 2i treated group, P5091 application
caused a significant decrease in C-MYC, KLF4, AXIN, and
β-Catenin gene expression levels by 10-fold, 38-fold, 4.3fold, and 2.5-fold, respectively. No significant change was
observed in expression levels of USP7, SOX2, Brachyury,
SNAIL, CHD1, and WNT3a genes. Also, USP7 inactivation
reduced SOX2 (37.5-fold), C-MYC (5.5-fold), AXIN (2.12fold), and WNT3a (3.2-fold) gene expression levels in LIF
treatment group. Yet, there was no significant change in
USP7, OCT4 and β-Catenin gene expression levels in LIF
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treatment group. Furthermore, noticeable change was not
detected in gene expression levels of Brachyury, Vimentin,
CDH1 and SNAIL in all experimental groups (Figure 3).
The experimental setup was also replicated without 2i

application, in M15 medium. Similar to 2i + LIF group,
a significant decrease in SOX2 (17.8-fold), OCT4 (3.4fold), KLF4 (5.4-fold), WNT3a (8.3-fold) and β-Catenin
(1.8-fold) was observed (Supplementary Figure 1).

Figure 3. P5091 treatment decreased the gene expression levels of pluripotency related SOX2, C-MYC, OCT4, and KLF4 genes. However,
no significant change was observed in mesoderm (Brachyury), ectoderm (Vimentin), and extra cellular matrix (SNAIL, CDH1) related
gene expression levels. Furthermore, USP7 inactivation caused a decrease in expressions of AXIN, WNT3a, and β-Catenin genes.
GAPDH mRNA was used as an external control. USP7 Ubiquitin Specific Protease 7, SOX2 SRY (sex determining region Y)-box 2,
OCT4 Octamer-binding transcription factor 4, KLF4 Kruppel Like Factor 4, SNAIL1 Snail Family Transcriptional Repressor 1, CDH1
Cadherin 1, WNT3a Wnt Family Member 3A, GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase, 2i CHIR99021 (3 μM) and
PD0325901 (1 μM) treatment, LIF Leukemia inhibitory factor, mean ± SD; n = 3 independent experiments; one-way ANOVA, *p < 0.05.

88

HAYAL / Turk J Biol
Nevertheless, no significant change in C-MYC, Brachyury,
SNAIL, and CDH1 was observed (Supplementary Figure
1).
3.4. Protein amounts of pluripotency related genes were
altered due to USP7 inactivation
To further examine the effect of USP7 on pluripotency
of mESCs, western blot analysis was conducted.
Experimental compressions were performed on the same
treatment groups with different USP7 activation status.
P5091 treatment caused no change in USP7 protein
amount significantly in ERK and GSK3β inhibited groups.
Interestingly, USP7 protein levels were decreased by 50%
after P5091 treatment in LIF treatment group (Figure 4).
Nanog protein amount decreased in combinational 2i +
LIF treatment group and individual 2i or LIF treatment
groups by 82%, 33%, and 11%, respectively. Similarly,
pluripotency related OCT4 protein level was found to be
decreased in 2i (30%), LIF (24%) and combination of 2i and
LIF (68%) groups after USP7 inactivation. Protein amount
of c-Myc was also observed to be decreased significantly
in 2i + LIF group by (47%), in 2i group by (12%) and in
LIF treatment group by 70%. Correspondingly, amount
of SOX2 protein also decreased after USP7 inactivation in
all experimental groups by 50% (2i + LIF), 72% (2i) and
75% (LIF). Although GSK3β was inhibited by 2i treatment,
USP7 inactivation in LIF treatment group resulted in a
significant increase in GSK3β protein amount (72.3%).
Furthermore, protein amount of β-Catenin reduced
dramatically after P5091 treatment in 2i (9%), LIF (7%) and
2i + LIF (84%) groups (Figure 4). Overall, these findings
suggest that USP7 enzyme activity not only maintains the
pluripotency of mESCs but also protects β-Catenin from
proteasomal degradation.
3.5. USP7 inactivation decreases half-life of GSK3β and
β-Catenin proteins
To evaluate the effect of USP7 inactivation on half-life of
USP7, c-Myc, Sox2, Oct4, Nanog, GSK3β and β-Catenin
proteins, the protein synthesis was blocked by CHX
treatment for different time points (1 h, 2 h, and 4 h).
GAPDH protein was used as an internal control. CHX
treatment for 4 h did not affect the USP7 levels in both
control and P5091 treatment groups. However, the protein
amount of Sox2 decreased by approximately 15% after
each hour in both control and P5091 groups. The amount
of c-Myc protein decreased by 16%, 25%, and 35% after 1
h, 2 h, and 4 h of CHX treatments, respectively. However,
no significant decrease was observed after 2 h of CHX
treatment, one hour of CHX treatment cause a noteworthy
decrease (35%) in c-Myc protein amount in P5091
treatment group. Unsurprisingly, the amount of c-Myc
protein dropped significantly after 4 h of CHX treatment
(15%) after P5091 treatment. A remarkable decrease
in the protein amount of Oct4 was noted after 1h CHX
treatment (approximately 64% in both control and P5091

treatment group). CHX treatment for 4 h causes a similar
decrease in OCT4 in both experimental groups. Likewise,
the protein amount of Nanog protein dropped coherently
in both control and P5091 treatment groups. Additionally,
the half-life of GSK3β and β-Catenin shortened after
P5091 treatment. Although, 1 h of CHX treatment did not
change GSK3β protein amount in control group, it caused
a significant decrease (37%) in P5091 treated group.
Correspondingly, 2 h and 4 h of CHX treatment decreased
GSK3β protein amount even more dramatically after USP7
inactivation (after 2 h treatment, 30% and 55% decrease in
control and P5091 treatment groups respectively; after 4
h treatment 32% and 40% decrease in control and P5091
treatment groups). Similarly, 1h and 2h of CHX treatment
did not change β-Catenin amount in control group. Yet,
USP7 inactivation cause a decrease in β-Catenin protein
amount even after 1 h and 2 h of CHX treatment (by 12%
and 50%, respectively). Also, 60% of β-Catenin remained
functional in control group while 20% of β-Catenin
remained functional in P5091 treatment group after 4 h
of CHX treatment (Figure 5). These findings strongly
suggest that USP7 inactivation shortens the half-lives of
GSK3β and β-Catenin, disturbing the maintenance of
pluripotency in mESCs.
4. Discussion
Post-translational regulation of proteins is usually
controlled by ubiquitination which plays a significant role
in almost every molecular pathway such as Wnt/β-catenin
pathway (Gao et al., 2014) which is critical for pluripotency
maintenance (Xu et al., 2016). The ubiquitination process
is controlled by de-ubiquitination enzymes (DUBs),
which can both block the ubiquitination sides of proteins
and detach the ubiquitination tags from target proteins
(Buckley, et al. 2012). As a DUB family member, USP7
is a perfect example for this kind of regulation (Nijman,
et al. 2005). Therefore, in the current study, we aimed to
identify the role of USP7 on pluripotency maintenance of
mESCs. The impact of USP7 activation on pluripotency
was evaluated after USP7 inactivation by small molecule
inhibitor, P5091. Previous studies successfully identified
P5091 as a specific molecular inhibitor for USP7 enzyme
activity (Chauhan et al., 2012). The results demonstrate
that high concentrations of P5091 show a toxic effect on
mESCs. However, 600 nM P5091 treatment shows no
significant effect on the viability of mESCs. Additionally,
600 nM P5091 treatment increases the total ubiquitination
amount in mESCs indicating the successful inhibition of
USP7 enzyme activity.
It is known in the literature that pluripotency
maintenance can be observed by morphological analysis
(Ye et al., 2017). Moreover, mESCs were assessed for ALP
activity. The literature have shown that ALP activity is
highly correlated with pluripotency of embryonic stem cells
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Figure 4. P5091 treatment decreased the protein levels of pluripotency related SOX2, C-MYC, OCT4 and NANOG genes. Inactivation
of USP7 activity increased the protein amount of GSK3β and reduced the β-Catenin significantly. A. Immunoblot images taken by
using imagining system. B. Band intensity calculations of various proteins relative to GAPDH. USP7 Ubiquitin Specific Protease 7,
SOX2 SRY (sex determining region Y)-box 2, OCT4 Octamer-binding transcription factor 4, NANOG Nanog Homeobox, GSK3β
Glycogen Synthase Kinase 3 Beta, GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase, 2i CHIR99021 (3 μM) and PD0325901 (1
μM) treatment, LIF Leukemia inhibitory factor, ns not significant, mean ± SD; n = 3 independent experiments; one-way ANOVA, #p ≤
0.001, *p < 0.05.
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Figure 5. Blocked ribosomal translation via cycloheximide treatment shortens the half-life of GSK3β and β-Catenin proteins. Yet,
no significant change was observed in the half-life of pluripotency related proteins after 4 h of treatment. The experiment was
conducted in the presence of M15 medium. A. Immunoblot images taken by using imagining system. B. Band intensity calculations
of various proteins relative to GAPDH. USP7 Ubiquitin Specific Protease 7, SOX2 SRY (sex determining region Y)-box 2, GSK3β
Glycogen Synthase Kinase 3 Beta, GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase, OCT4 Octamer-binding transcription
factor 4, NANOG Nanog Homeobox, CHX cycloheximide, ns not significant, mean ± SD; n = 3 independent experiments; one-way
ANOVA, *p < 0.05.

(Phay et al., 2021). Obtained results have demonstrated
that allosteric inhibition of USP7 altered the morphology
and ALP activity of mESCs in 2i or LIF treatment groups.
It was previously stated that dual inhibitory application

(GSK3 and MEK inhibitors) is required for morphological
and pluripotency maintenance of mESCs (Petkov et al.,
2014). However, inactivation of USP7 by 600 nM of P5091
treatment changed the cellular morphology and lessened
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the ALP activity of mESCs even in 2i treated groups
suggesting the failure to maintain pluripotency without
active USP7 enzyme. The reduction in the ALP activity
of mouse embryonic stem cells also clarified that even in
M15 medium, which supports pluripotency without GSK3
and MEK inhibitors (Yang et al., 2017), P5091 treatment is
responsible for decreasing pluripotency.
Several studies have focused on transcription factors
that are required for keeping embryonic stem cells at
pluripotent state (Takahashi and Yamanaka 2006). The
transcription factors, Nanog, Oct4, Sox2, c-Myc and Klf4,
play an important role in both pluripotency maintenance
and reprogramming of somatic cells into inducepluripotent stem cells (iPSCs) (Takahashi and Yamanaka
2006). Obtained results indicated that expression levels
of pluripotency related SOX2, C-MYC, OCT4 and KLF4
genes decreased, but no significant change in mesoderm
and ectoderm markers, T/BRA and Vimentin, respectively
was observed after USP7 inactivation. This finding suggests
that no significant change in ectodermal or mesodermal
differentiation has been noted, although the inactivation
of USP7 decreases the pluripotency. Gene expression
analysis was also supported by Western Blot analysis.
Decreased protein levels of pluripotency related Nanog,
Oct4, c-Myc, and Sox2 transcription factors were observed.
Previous studies have addressed the relationship between
deubiquitinase activity and pluripotency maintenance
(Suresh, et al. 2016). For instance, deubiquitination
enzyme, USP21, can control pluripotency by stabilization
of transcriptional factor, Nanog (Pei, 2017). Moreover,
USP9X as a deubiquitinase was found to regulate early
differentiation process of stem cells (Suresh et al., 2016).
Also, USP22 regulates various pluripotency related
transcription factors such as Sox2 and c-Myc (Suresh et
al., 2016), which were observed to be actively expressed
in human ESCs and iPSCs (Sridharan et al., 2009). USP7
was also correlated with the maintenance of stem cell
properties. Huang et. al. conducted a study to identify USP7
and repressor element 1-silencing transcription factor
(REST) relationship to increase neural stem/progenitor
cell maintenance (Huang et al., 2011). In the current
study, it was observed that USP7 inhibition also resulted
in a significant decrease in WNT3a, AXIN and β-Catenin
gene expression levels. It is known that USP7 stabilizes
both Axin and β-catenin (Wang et al., 2019). This dual
effect of USP7 makes it really unique enzyme to control
Wnt/β-catenin pathway. Not surprisingly, protein amount
of β-catenin was also found to be decreased in all P5091
treatment groups. M15 medium was also used to support
these findings. It is known that Wnt/β-catenin signaling
is affected by dual inhibition of GSK3 and MEK (Liao et
al., 2018; Kwon et al., 2019). Thus, M15 medium was used
to demonstrate the exact effect of USP7 inactivation on
Wnt/β-catenin pathway. Obtained results were found to
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correlate positively with the dual inhibitory groups; the
expression levels of pluripotency related genes as well as
GSK3β and β-catenin expression were found to decrease
dramatically due to P5091 treatment.
The effect of USP7 inhibition on pluripotency
maintenance was further examined by half-life
determination of pluripotency related proteins. The
literature reveals that cycloheximide (CHX) treatment
successfully blocks the protein synthesis in cells (Wittstock
et al., 1993); thus, it can be used to examine the changes in
half-life of proteins (Yang, et al. 2017). In the current study
the protein synthesis of R1/E cells were inhibited by 50 μg/
ml CHX treatment and alterations in pluripotency related
protein half-lives were demonstrated by immunoblotting.
It was shown in the literature that the half-life of USP7
protein was not affected by 50 μg/mL CHX treatment
for four hours (Peng et al., 2019). Therefore, it can be
suggested that observed alterations in half-life of proteins
is due to USP7 inactivation. The result of this study reveals
that USP7 inactivation significantly shortens the half-live
of both GSK3β and β-catenin compared to control group.
There was no significant change observed between control
and P5091 treated groups in half-life of pluripotency
related Sox2, c-Myc, Oct4, and Nanog proteins. These
results show for the first time in the literature that USP7
plays a critical role in pluripotency maintenance by its
ability to regulate β-Catenin stability.
Previously it was clarified that Wnt/β-catenin signaling
is vital for pluripotency maintenance of mESCs (ten Berge
et al., 2011). Unwanted differentiation of mESCs is blocked
by the application of small molecule inhibitor of GSK3,
CHIR99021, which works as an activator of Wnt/β-catenin
pathway (Wu et al., 2013). Furthermore, LIF treatment
triggers the JAK/STAT signaling pathway, which eventually
inhibits the GSK3 (Ogawa et al., 2006). Dual inhibition
of GSK3 and MEK is traditionally preferred in order to
maintain pluripotency (Ying et al., 2008). Interestingly,
there are several studies suggesting that inhibition of
Wnt/β-catenin promotes pluripotency maintenance
(Davidson et al., 2012). Thus, it is important to know the
homeostatic role of Wnt/β-catenin pathway on pluripotent
stem cells. It was shown in the literature that Wnt signaling
pathway is required for proper differentiation, yet cellular
adhesion related, CDH1 independent cytoplasmic activity
of β-catenin is important for pluripotency maintenance
(Sineva and Pospelov 2014). The results of the current
study demonstrated no significant change in CDH1 and
SNAIL gene expression levels after P5091 treatment.
Therefore, a decrease in β-catenin gene expression
level after USP7 inhibition might be correlated with the
decreased pluripotency capacity of mESCs.
It was also demonstrated that USP7 plays a dual role
in the regulation of Wnt/β-catenin pathway (Park et al.,
2020). USP7 deubiquitinates Axin protein, which is a
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part of a complex that inhibits β-catenin protein. Thus,
USP7 acts as an inhibitor of Wnt/β-catenin pathway (Ji
et al., 2019). Contrarily, it is known in the literature that
USP7 deubiquitinase activity rescues β-catenin protein
from proteasomal degradation via its interaction with E3
ligase RNF220. Thus, USP7 also upregulates the β-catenin
stability (Ma et al., 2014). These findings suggest that
USP7 enzyme has a dual effect on Wnt/β-catenin pathway,
which has a dual effect on pluripotency and stem cell
differentiation. Therefore, USP7 enzyme activity, which
is essential for post-translational protein regulation, is
responsible for balancing pluripotency maintenance and
differentiation decisions of mESCs in vitro.
5. Conclusion
Overall, USP7, as a deubiquitinase, might be very
important for striking the balance between differentiation
and pluripotency maintenance of mESCs. This study
indicates that allosteric inhibition of USP7 decreases the

levels of pluripotency related Sox2, Nanog, Oct4, Klf4 and
c-Myc genes, and proteins through the posttranslational
regulation of GSK3β and β-Catenin correlation in mESCs.
Furthermore, USP7 inactivation significantly shortens the
half-life of β-catenin protein. The real impact of USP7/
β-catenin correlation on pluripotency maintenance of
mESCs should be further investigated to clarify the exact
molecular mechanism that underlies.
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Supplementary Figure 1. USP7 inactivation decreases pluripotency of mESCs in M15 medium. A. USP7 inactivation changes the
morphology of mESCs in vitro. B. P5091 treatment causes a significant decrease in ALP activity of mESCs in M15 medium. Histogram
shows the decrease in ALP activity in each group. C. P5091 treatment decreased the gene expression levels of pluripotency related SOX2,
OCT4 and KLF4 genes in M15 medium. However, no significant change was observed in mesoderm (Brachyury) and extra cellular
matrix (SNAIL, CDH1) related gene expression levels. Furthermore, USP7 inactivation caused a decrease in expressions of WNT3a
and β-Catenin genes. GAPDH mRNA was used as an external control. USP7 Ubiquitin Specific Protease 7, SOX2 SRY (sex determining
region Y)-box 2, OCT4 Octamer-binding transcription factor 4, KLF4 Kruppel Like Factor 4, SNAIL Snail Family Transcriptional
Repressor 1, CDH1 Cadherin 1, WNT3a Wnt Family Member 3A, GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase, mean ± SD; n
= 3 independent experiments; one-way ANOVA, *p < 0.05, compared with the M15 medium control group.
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